Company intelligence / Profile preview
InventisBio
Shanghai/Pudong New Area, Shanghai, Chinainventisbio.com ↗
- Ownership
- Private
- Employees
- ~221
- Development stage
- Commercial
01
Overview
InventisBio has two drugs approved in China and three additional candidates in clinical trials. The most advanced program is in Phase 3 registration trials. Notably, their KRAS G12C inhibitor "Garsorasib" received market authorization from the NMPA of China for NSCLC and has been added to the Breakthrough Therapy Designation Program for new indications. Their TYK2 inhibitor D2570 showed positive results in a Phase 2 study for moderate to severe plaque psoriasis.
- Therapeutic areas
- OncologyImmunologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Betta Pharmaceuticals collaboration agreement
Beyond the preview
Go deeper on InventisBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InventisBio.